Skip to main content
NCBI home page
American Journal of Public Health logoLink to American Journal of Public Health
. 1993 May;83(5):711–716. doi: 10.2105/ajph.83.5.711

Treatment for glaucoma: adherence by the elderly.

J H Gurwitz 1, R J Glynn 1, M Monane 1, D E Everitt 1, D Gilden 1, N Smith 1, J Avorn 1
PMCID: PMC1694682  PMID: 8484454

Abstract

OBJECTIVES. The purpose of this study was to determine the extent of nonadherence to treatment for glaucoma among elderly patients. METHODS. This was a retrospective cohort study of 2440 patients older than age 65 who were enrolled in the New Jersey Medicaid Program and who were newly initiated on a topical agent for the treatment of glaucoma. Two patient-specific measures of nonadherence were employed: (1) no filled prescription for any glaucoma medication over a 12-month period after the initiation of therapy and (2) number of days without therapy for glaucoma during this 12-month period. RESULTS. By the first measure, 569 patients (23%) were found to be nonadherent. The mean number of days without therapy during the study year was 112. Factors associated with nonadherence included the use of glaucoma medication requiring more than 2 administrations per day and the presence of multiple other medications in the patient's drug regimen. Patients started on multiple glaucoma medication were more adherent than those started on a single agent. Age and sex were not found to be predictors of nonadherence. CONCLUSIONS. Substantial nonadherence was found to be common in this population. More attention to the issue of nonadherence could result in important benefits in the preservation of sight.

Full text

PDF
711

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avorn J., Soumerai S. B. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing". N Engl J Med. 1983 Jun 16;308(24):1457–1463. doi: 10.1056/NEJM198306163082406. [DOI] [PubMed] [Google Scholar]
  2. Avorn J. The elderly and drug policy: coming of age. Health Aff (Millwood) 1990 Fall;9(3):6–19. doi: 10.1377/hlthaff.9.3.6. [DOI] [PubMed] [Google Scholar]
  3. Bloch S., Rosenthal A. R., Friedman L., Caldarolla P. Patient compliance in glaucoma. Br J Ophthalmol. 1977 Aug;61(8):531–534. doi: 10.1136/bjo.61.8.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Darnell J. C., Murray M. D., Martz B. L., Weinberger M. Medication use by ambulatory elderly. An in-home survey. J Am Geriatr Soc. 1986 Jan;34(1):1–4. doi: 10.1111/j.1532-5415.1986.tb06332.x. [DOI] [PubMed] [Google Scholar]
  5. Eisen S. A., Miller D. K., Woodward R. S., Spitznagel E., Przybeck T. R. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990 Sep;150(9):1881–1884. [PubMed] [Google Scholar]
  6. Epstein D. L., Krug J. H., Jr, Hertzmark E., Remis L. L., Edelstein D. J. A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology. 1989 Oct;96(10):1460–1467. doi: 10.1016/s0161-6420(89)32688-1. [DOI] [PubMed] [Google Scholar]
  7. Eraker S. A., Kirscht J. P., Becker M. H. Understanding and improving patient compliance. Ann Intern Med. 1984 Feb;100(2):258–268. doi: 10.7326/0003-4819-100-2-258. [DOI] [PubMed] [Google Scholar]
  8. Evans L., Spelman M. The problem of non-compliance with drug therapy. Drugs. 1983 Jan;25(1):63–76. doi: 10.2165/00003495-198325010-00004. [DOI] [PubMed] [Google Scholar]
  9. Everitt D. E., Avorn J. Systemic effects of medications used to treat glaucoma. Ann Intern Med. 1990 Jan 15;112(2):120–125. doi: 10.7326/0003-4819-112-2-120. [DOI] [PubMed] [Google Scholar]
  10. Federspiel C. F., Ray W. A., Schaffner W. Medicaid records as a valid data source: the Tennessee experience. Med Care. 1976 Feb;14(2):166–172. doi: 10.1097/00005650-197602000-00006. [DOI] [PubMed] [Google Scholar]
  11. Gallup G., Jr, Cotugno H. E. Preferences and practices of Americans and their physicians in antihypertensive therapy. Am J Med. 1986 Dec 31;81(6C):20–24. doi: 10.1016/0002-9343(86)90524-3. [DOI] [PubMed] [Google Scholar]
  12. Granström P. A. Progression of visual field defects in glaucoma. Relation to compliance with pilocarpine therapy. Arch Ophthalmol. 1985 Apr;103(4):529–531. doi: 10.1001/archopht.1985.01050040071020. [DOI] [PubMed] [Google Scholar]
  13. JOYCE C. R. Patient co-operation and the sensitivity of clinical trials. J Chronic Dis. 1962 Nov;15:1025–1036. doi: 10.1016/0021-9681(62)90123-6. [DOI] [PubMed] [Google Scholar]
  14. Kass M. A. Compliance and prognosis in glaucoma. Arch Ophthalmol. 1985 Apr;103(4):504–504. doi: 10.1001/archopht.1985.01050040046014. [DOI] [PubMed] [Google Scholar]
  15. Kass M. A., Gordon M. O., Hoff M. R., Parkinson J. M., Kolker A. E., Hart W. M., Jr, Becker B. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial. Arch Ophthalmol. 1989 Nov;107(11):1590–1598. doi: 10.1001/archopht.1989.01070020668025. [DOI] [PubMed] [Google Scholar]
  16. Kass M. A., Gordon M., Morley R. E., Jr, Meltzer D. W., Goldberg J. J. Compliance with topical timolol treatment. Am J Ophthalmol. 1987 Feb 15;103(2):188–193. doi: 10.1016/s0002-9394(14)74225-4. [DOI] [PubMed] [Google Scholar]
  17. Kass M. A., Meltzer D. W., Gordon M., Cooper D., Goldberg J. Compliance with topical pilocarpine treatment. Am J Ophthalmol. 1986 May 15;101(5):515–523. doi: 10.1016/0002-9394(86)90939-6. [DOI] [PubMed] [Google Scholar]
  18. Kass M. A. Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: a five-year, randomized, double-masked, clinical trial. Trans Am Ophthalmol Soc. 1989;87:598–618. [PMC free article] [PubMed] [Google Scholar]
  19. Lonergan E. T., Krevans J. R. A national agenda for research on aging. N Engl J Med. 1991 Jun 20;324(25):1825–1828. doi: 10.1056/NEJM199106203242527. [DOI] [PubMed] [Google Scholar]
  20. Norell S. E. Monitoring compliance with pilocarpine therapy. Am J Ophthalmol. 1981 Nov;92(5):727–731. doi: 10.1016/s0002-9394(14)74670-7. [DOI] [PubMed] [Google Scholar]
  21. Podgor M. J., Leske M. C., Ederer F. Incidence estimates for lens changes, macular changes, open-angle glaucoma and diabetic retinopathy. Am J Epidemiol. 1983 Aug;118(2):206–212. doi: 10.1093/oxfordjournals.aje.a113628. [DOI] [PubMed] [Google Scholar]
  22. Schaffner W., Ray W. A., Federspiel C. F., Miller W. O. Improving antibiotic prescribing in office practice. A controlled trial of three educational methods. JAMA. 1983 Oct 7;250(13):1728–1732. [PubMed] [Google Scholar]
  23. Soumerai S. B., Avorn J., Ross-Degnan D., Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med. 1987 Aug 27;317(9):550–556. doi: 10.1056/NEJM198708273170906. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES